Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026
Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has accepted...
BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
Bristol-Myers Squibb (BMS) (NYSE: BMY) announced a strategic partnership with the Tigerlily Foundation, a leading...
Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that its Phase III clinical trial evaluating fianlimab (LAG-3...
AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing...
Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
Harbour BioMed (HKG: 2142) has published preclinical data for LET003, an ACVR2A/2B-targeted monoclonal antibody (mAb)...
Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals...
AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
AstraZeneca (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug...
Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA)...
Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Biogen Inc. (NASDAQ: BIIB) announced that zorevunersen, an investigational antisense oligonucleotide (ASO) for Dravet syndrome,...
Shanghai CureGene’s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial – First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance
Shanghai CureGene Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Shenzhen Salubris Secures Chinese Approval for Xinfutai Plus – First Once-Weekly Teriparatide for High-Risk Postmenopausal Osteoporosis
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced market approval from China’s National Medical Products...
Changchun GeneScience’s GenSci161 Receives FDA Clearance for Hidradenitis Suppurativa Clinical Trial – Novel Bispecific Antibody Targeting IL-1α/IL-1β
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun...
Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
Alibaba Health Information Technology Ltd. (HKG: 0241) released its fiscal year 2026 financial results for...
Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Amgen Inc. (NASDAQ: AMGN) announced that China’s National Medical Products Administration (NMPA) has accepted for...
China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
China’s National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) issued...
Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced it has received clinical trial approval...
AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
AstraZeneca plc (NYSE: AZN) released high-level results from a prespecified interim analysis of the Phase...
Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes
Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical...
Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease
Biogen Inc. (NASDAQ: BIIB) announced positive top-line results from the Phase II CELIA study, evaluating...
Hengrui Pharmaceuticals Secures NMPA Clinical Approval for RSS0393 Latex in Atopic Dermatitis Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical approval...